IN2014MN02060A - - Google Patents

Info

Publication number
IN2014MN02060A
IN2014MN02060A IN2060MUN2014A IN2014MN02060A IN 2014MN02060 A IN2014MN02060 A IN 2014MN02060A IN 2060MUN2014 A IN2060MUN2014 A IN 2060MUN2014A IN 2014MN02060 A IN2014MN02060 A IN 2014MN02060A
Authority
IN
India
Prior art keywords
amino acid
amount
clinical condition
biological material
index value
Prior art date
Application number
Other languages
English (en)
Inventor
Kenji Hamase
Yousuke Toujo
Masashi Mita
Chieko Mizumoto
Original Assignee
Univ Kyushu Nat Univ Corp
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyushu Nat Univ Corp, Shiseido Co Ltd filed Critical Univ Kyushu Nat Univ Corp
Publication of IN2014MN02060A publication Critical patent/IN2014MN02060A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/89—Inverse chromatography
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8818—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8877—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2060MUN2014 2012-03-18 2013-03-18 IN2014MN02060A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012061305 2012-03-18
PCT/JP2013/001849 WO2013140785A1 (ja) 2012-03-18 2013-03-18 疾患サンプル分析装置、分析システム及び分析方法

Publications (1)

Publication Number Publication Date
IN2014MN02060A true IN2014MN02060A (enrdf_load_stackoverflow) 2015-08-21

Family

ID=49222264

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2060MUN2014 IN2014MN02060A (enrdf_load_stackoverflow) 2012-03-18 2013-03-18

Country Status (7)

Country Link
US (2) US20150079623A1 (enrdf_load_stackoverflow)
EP (3) EP3663758A1 (enrdf_load_stackoverflow)
JP (3) JP6037388B2 (enrdf_load_stackoverflow)
CN (11) CN110133298A (enrdf_load_stackoverflow)
IN (1) IN2014MN02060A (enrdf_load_stackoverflow)
TW (2) TWI615614B (enrdf_load_stackoverflow)
WO (1) WO2013140785A1 (enrdf_load_stackoverflow)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015087985A1 (ja) 2013-12-11 2015-06-18 株式会社資生堂 腎不全の早期診断マーカー
CN107683414A (zh) * 2015-06-10 2018-02-09 国立大学法人金泽大学 肾病的病态生物标志物
CN108587991B (zh) * 2015-10-10 2021-03-05 中国科学院南海海洋研究所 一种高产环肽类化合物的菌株
US11099191B2 (en) 2016-05-17 2021-08-24 Osaka University Kidney disease prognosis prediction method and system
EP3460478A4 (en) * 2016-05-17 2020-01-08 Osaka University BLOOD SAMPLE ANALYSIS METHOD AND SYSTEM FOR DETERMINING DIABETES
CN109923413A (zh) 2016-11-15 2019-06-21 株式会社资生堂 多级色谱分析方法及分析系统
WO2018159833A1 (ja) * 2017-03-02 2018-09-07 株式会社ニコン 細胞の判別方法、がんの検査方法、計測装置、がんの検査装置および検査プログラム
SG11201908102TA (en) 2017-03-03 2019-10-30 Shiseido Co Ltd Novel compound, fluorescence derivatization reagent including said novel compound, method for optically resolving optical isomer of amino acid in which said novel compound is used, and fluorescence derivatized amino acid
US12220394B2 (en) 2018-06-07 2025-02-11 National University Corporation Kanazawa University Pharmaceutical composition for prevention or treatment of kidney damage
JP7366428B2 (ja) * 2018-08-27 2023-10-23 Kagami株式会社 乾癬を判定するための皮膚試料の分析方法及びシステム
US12360117B2 (en) 2018-10-17 2025-07-15 Kagami Inc. Method for determining glomerular filtration ability
US20220170945A1 (en) * 2019-03-22 2022-06-02 Kagami Inc. Method for assisting evaluation of renal pathological conditions, system for evaluating renal pathological conditions and program for evaluating renal pathological conditions
JP7434678B2 (ja) 2019-05-20 2024-02-21 花王株式会社 認知症又はそのリスクの検査方法
EP4083628A4 (en) 2019-12-27 2024-02-21 Kagami Inc. Method and system for estimating renal function
CN112180007B (zh) * 2020-09-16 2023-08-18 上海市皮肤病医院 基于代谢组学的泛发性脓疱型银屑病诊断标志物及其应用
CN111899883B (zh) * 2020-09-29 2020-12-15 平安科技（深圳）有限公司 少样本或零样本的疾病预测设备、方法、装置及存储介质
JP7600016B2 (ja) 2021-03-30 2024-12-16 花王株式会社 高次脳機能の測定方法
WO2023033178A1 (ja) * 2021-09-03 2023-03-09 Kagami株式会社 癌についての情報を提供する方法、癌についての情報を提供するシステム及び癌を治療する方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4290893A (en) * 1979-05-08 1981-09-22 Yeda Research & Development Co. Ltd. Separation of amino acids by liquid chromatography using chiral eluants
CA2030212A1 (en) * 1989-11-22 1991-05-23 Judson V. Edwards Peptides
US5374651A (en) * 1991-09-27 1994-12-20 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives
AU5360796A (en) * 1995-03-09 1996-10-02 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
JPH0975078A (ja) * 1995-09-13 1997-03-25 Ikeda Shokken Kk 耐熱性ｄ−アミノ酸オキシダーゼ、その製造法および微生物
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
EP0882736A1 (en) * 1997-06-02 1998-12-09 Laboratoire Theramex S.A. LH-RH peptide analogues, their uses and pharmaceutical compositions containing them
DE69911771D1 (de) * 1998-06-11 2003-11-06 Fox Chase Cancer Ct Philadelph Methoden zur ermittlung des risikos eines diabetikers für einen mit diabetes in zusammenhang stehenden pathologischen zustand
CA2373314C (en) * 1999-05-14 2010-09-14 Brandeis University Nucleic acid-based detection
US6479063B2 (en) * 1999-12-27 2002-11-12 Kenneth Weisman Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
US7223558B2 (en) * 2001-07-11 2007-05-29 Bristol-Myers Squibb Company Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
CA2475953A1 (en) * 2002-02-27 2003-09-04 E. Ann Tallant Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
FR2838444B1 (fr) * 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
US20070298041A1 (en) * 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
JP4299243B2 (ja) * 2002-07-04 2009-07-22 田辺三菱製薬株式会社 統合失調症の検査、診断方法
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
GB0223424D0 (en) * 2002-10-09 2002-11-13 Imp College Innovations Ltd Disease-associated gene
AU2003289263A1 (en) * 2002-12-09 2004-06-30 Ajinomoto Co., Inc. Organism condition information processor, organism condition information processing method, organism condition information managing system, program, and recording medium
EP1577323B1 (en) * 2002-12-26 2013-07-10 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
AU2003900777A0 (en) * 2003-02-21 2003-03-13 Medvet Science Pty. Ltd. A method of diagnosis and treatment
CA2518703A1 (en) * 2003-03-10 2004-09-23 Sionex Corporation Systems for differential ion mobility analysis
US20060217316A1 (en) * 2003-04-02 2006-09-28 Ragab El-Rashidy Method for the treatment of prostate cancer
JP4291628B2 (ja) 2003-06-12 2009-07-08 株式会社資生堂 液体クロマトグラフ装置及び試料に含まれる光学異性体の分析方法
CN1557823A (zh) * 2004-02-12 2004-12-29 窦德献 L-或d-氨基酸合铂配位体、制备方法及其用途
DE602005025211D1 (de) * 2004-04-09 2011-01-20 Us Gov Health & Human Serv Diagnosegerät zur diagnose gutartiger gegenüber bösartigen schilddrüsenläsionen
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
GB0417887D0 (en) * 2004-08-11 2004-09-15 Ares Trading Sa Protein
KR101286833B1 (ko) * 2005-03-18 2013-07-17 가부시키가이샤 시세이도 편평상피세포암 관련 항원을 지표로 하는 피부 성상의 평가방법
CN101189243A (zh) * 2005-04-06 2008-05-28 阿斯利康(瑞典)有限公司 取代的杂环及其作为chk1、pdk1和pak抑制剂的应用
JP2007077104A (ja) * 2005-09-16 2007-03-29 Shiseido Co Ltd 血管内皮増殖因子阻害剤
WO2007103124A2 (en) * 2006-03-02 2007-09-13 Perkinelmer Las, Inc. Methods for distinguishing isomers using mass spectrometry
US20070258899A1 (en) * 2006-03-31 2007-11-08 Karyon-Ctt Ltd Diagnostic and therapeutic agents
JP5005955B2 (ja) * 2006-05-24 2012-08-22 田辺三菱製薬株式会社 被験物質の脂質代謝異常症誘発可能性を予測する方法
WO2008005469A2 (en) * 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
EP1900742A1 (en) * 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
BRPI0716190A2 (pt) * 2006-09-06 2013-11-12 Aeterna Zentaris Gmbh Conjugados de disorazóis e seus derivados com móleculas de ligação celular, derivados de disorazol, processos para fabricação e uso dos mesmos
US20090075284A1 (en) * 2006-09-19 2009-03-19 The Regents Of The University Of Michigan Metabolomic profiling of prostate cancer
EP2074092A2 (en) * 2007-01-18 2009-07-01 Sepracor Inc. Inhibitors of d-amino acid oxidase
JP2010518812A (ja) * 2007-02-12 2010-06-03 アンスロジェネシス コーポレーション 接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにｃｄ３４＋、ｃｄ４５−胎盤幹細胞の濃縮細胞集団
US8034780B2 (en) * 2007-07-16 2011-10-11 Mcphail Kerry Leigh Isolation, purification, and structure elucidation of the antiproliferative compound coibamide A
KR20110000548A (ko) * 2008-01-17 2011-01-03 도레이 카부시키가이샤 신장암의 진단 또는 검출을 위한 조성물 및 방법
JP2009184981A (ja) * 2008-02-07 2009-08-20 Shiseido Co Ltd 抗ｄ−アミノ酸モノクローナル抗体及び、抗ｄ−アミノ酸モノクローナル抗体を用いたｄ−アミノ酸の免疫学的分析方法
WO2009139497A1 (en) * 2008-05-14 2009-11-19 Takeda Pharmaceutical Company Limited Cbp501 -derived agents and methods based thereon for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
WO2009143489A2 (en) * 2008-05-22 2009-11-26 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
US20110311650A1 (en) * 2008-07-07 2011-12-22 Thomas Wang Multiplexed biomarkers of insulin resistance
JP2010038796A (ja) * 2008-08-06 2010-02-18 Human Metabolome Technologies Inc 疾患マーカー、および、疾患マーカーの測定方法
EP2338988B1 (en) * 2008-08-26 2015-09-16 Kyushu University, National University Corporation Evaluation/screening method for diseases associated with d-amino acid utilizing dao1-/- mouse
US8722343B2 (en) * 2008-11-21 2014-05-13 Carla Perego Methods and compositions for the diagnosis and treatment of diabetes
EP2249161B1 (en) * 2009-05-05 2020-05-13 InfanDx AG Method of diagnosing asphyxia
CN101619092B (zh) * 2009-08-06 2012-08-15 中国人民解放军第三军医大学第二附属医院 肿瘤抗原trag-3模拟表位肽及其应用
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
JP2011247869A (ja) * 2010-04-27 2011-12-08 Kobe Univ メタボローム解析手法を用いた特定疾患の検査方法
CN102079771B (zh) * 2010-12-10 2012-10-03 郑州大学 具有抗肿瘤活性的雌甾氨基酸酯化合物及其合成方法

Also Published As

Publication number Publication date
TW201344194A (zh) 2013-11-01
US20150079623A1 (en) 2015-03-19
US20190025320A1 (en) 2019-01-24
CN110161256B (zh) 2022-03-25
TWI615614B (zh) 2018-02-21
CN110133300B (zh) 2022-02-25
CN110133296A (zh) 2019-08-16
CN110133299A (zh) 2019-08-16
JP6037388B2 (ja) 2016-12-07
CN110133297A (zh) 2019-08-16
EP2829877B1 (en) 2020-01-22
CN110133298A (zh) 2019-08-16
CN114966050A (zh) 2022-08-30
CN110133301B (zh) 2022-03-22
EP3795997A1 (en) 2021-03-24
TWI664425B (zh) 2019-07-01
CN104246497B (zh) 2017-10-13
CN110161256A (zh) 2019-08-23
JP2017223711A (ja) 2017-12-21
EP2829877A1 (en) 2015-01-28
TW201736851A (zh) 2017-10-16
JP2013224929A (ja) 2013-10-31
CN110133300A (zh) 2019-08-16
EP3663758A1 (en) 2020-06-10
CN110133296B (zh) 2022-03-25
CN110133301A (zh) 2019-08-16
JP2017015741A (ja) 2017-01-19
EP2829877A4 (en) 2015-12-09
CN104246497A (zh) 2014-12-24
EP3795997B1 (en) 2022-08-24
WO2013140785A1 (ja) 2013-09-26
CN107449923A (zh) 2017-12-08
JP6214016B2 (ja) 2017-10-18
CN107449923B (zh) 2020-07-24
JP6391787B2 (ja) 2018-09-19
CN110133295A (zh) 2019-08-16

Similar Documents

Publication Publication Date Title
IN2014MN02060A (enrdf_load_stackoverflow)
EP2573192A4 (en) METHOD AND KIT FOR DIAGNOSING DISEASE ASSOCIATED WITH AIM
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
BR112015003715A8 (pt) análise de raman, de infravermelho, ou de raman-infravermelho da estrutura de proteína de plasma de sangue periférico e sua relação para desenvolvimento cognitivo no mal de alzheimer
GB2488700B (en) Methods for monitoring disease conditions by analysis of the full repertoire of CDR3 sequences of an individual
MX348392B (es) Sistemas y metodos para diagnostico de la salud.
WO2013040099A3 (en) Sepsis prognosis biomarkers
IN2014DN10121A (enrdf_load_stackoverflow)
WO2014074835A3 (en) Antibody compositions and immunoassay methods to detect isoforms of anti-mullerian hormone
WO2013190075A3 (en) Specific biomarkers for hepatocellular carcinoma (hcc)
WO2012078623A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
EP2579043A4 (en) DETECTION METHOD
TN2015000161A1 (en) Methylglyoxal as a marker of cancer
WO2009001545A1 (ja) 移植片対宿主疾患の検査および治療方法
WO2010099137A3 (en) In situ methods for monitoring the emt status of tumor cells in vivo
EA201700123A1 (ru) Способ прогнозирования варианта лекарственного препарата для лечения депрессии
PH12015500519A1 (en) Mitochondrial toxicity test
GB201102693D0 (en) Method for identifying neonates at risk for necrotizing enterocolitis
WO2012109258A3 (en) Compositions adn methods for monitoring oxalate
WO2012167887A8 (en) Diagnostic use of prosomatostatin
WO2012008747A3 (ko) 피부 진단 방법 및 키트
EA201200948A1 (ru) Метод определения функционального состояния печени живого существа путём количественного измерения метаболизации субстратов
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
BR112014007947A2 (pt) método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5
WO2014042148A8 (ja) がんマーカーおよびその用途